Welcome to our dedicated page for Danaher Corporation SEC filings (Ticker: DHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Danaher Corporation (NYSE: DHR) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings include current reports on Form 8‑K, quarterly reports on Form 10‑Q and other disclosures that detail Danaher’s financial performance, governance changes and capital markets activities as a global life sciences and diagnostics innovator.
Danaher uses Form 8‑K filings to report material events such as quarterly and annual financial results, estimated financial performance ahead of investor conferences, amendments to its by‑laws, share repurchase authorizations and changes in senior leadership or board composition. For example, the company has filed 8‑Ks to furnish earnings press releases and presentation slides, to describe updates to its by‑laws regarding shareholder proposal and nomination procedures, and to outline a share repurchase program authorizing the repurchase of up to 35 million shares of common stock.
The filings also list Danaher’s securities registered under Section 12(b) of the Exchange Act, including its common stock and multiple series of senior notes with various maturities, all traded on the New York Stock Exchange. This information helps investors understand the company’s capital structure and the instruments available in public markets.
Through its periodic reports, Danaher provides detailed financial statements, management’s discussion and analysis, and explanations of non‑GAAP measures such as core sales growth and adjusted diluted net earnings per common share. The company explains how it calculates these measures, why management uses them and how they reconcile to the most directly comparable GAAP figures, including adjustments for amortization of acquisition‑related intangible assets, fair value gains and losses on investments, impairments and tax effects.
On Stock Titan, users can review these SEC filings alongside AI‑powered summaries that highlight key points, such as revenue trends, margin drivers, capital allocation decisions, governance changes and risk disclosures. The platform’s tools can help readers quickly understand the implications of Danaher’s 10‑Q and 10‑K reports, as well as 8‑K items related to dividends, share repurchases, executive transitions and by‑law amendments, while still allowing detailed review of the original documents.
Danaher Corporation reported results from its May 5, 2026 annual shareholder meeting. Shareholders approved an Amended and Restated Omnibus Incentive Plan that increases the plan’s share reserve by 20 million shares of common stock and extends its term to May 5, 2036.
All eleven director nominees were elected with strong majorities, and shareholders ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. Shareholders also approved, on an advisory basis, the company’s named executive officer compensation and formally approved the incentive plan itself.
Danaher director Alan G. Spoon exercised stock options and sold a portion of the resulting shares. He exercised options to acquire 3,298 shares of Danaher common stock at an exercise price of $71.88 per share, then sold 1,358 shares in an open-market transaction at a weighted average price of $174.6737 per share, with individual sale prices ranging from $174.67 to $174.72.
After these transactions, Spoon holds 124,093.689 shares of Danaher common stock directly and 8,700 shares indirectly through an LLC, indicating that the sale represents a relatively small part of his overall position.
Danaher Corp reports a Schedule 13G stake held by Vanguard Capital Management. Vanguard Capital Management beneficially owns 47,383,707 shares of Common Stock, representing 6.69% of the class as of 03/31/2026. The filing shows sole voting power of 6,255,897 shares and sole dispositive power over 47,383,707 shares. The filing notes these holdings include shares held for Vanguard funds and managed accounts and lists affiliated management entities. The form is signed on 04/29/2026.
Danaher Corporation completed a major euro-denominated debt offering to help finance its proposed acquisition of Masimo Corporation. The company issued €500 million of Floating Rate Senior Notes due 2028, €750 million of 3.250% Senior Notes due 2030, €750 million of 3.625% Senior Notes due 2034 and €1.0 billion of 4.000% Senior Notes due 2038.
Danaher received net proceeds of approximately €2.98 billion, which it plans to use primarily to pay a portion of the cash consideration and related costs for the Masimo acquisition, with any remainder available for general corporate purposes. The fixed-rate notes include a special mandatory redemption at 101% of principal plus interest if the Masimo deal is not completed under the merger agreement timeline, and investors also receive a 101% change-of-control repurchase right. The notes are unsecured senior obligations and include covenants limiting certain liens, sale-leasebacks and major structural transactions.
Danaher Corporation director Raymond C. Stevens received a compensation-related grant of phantom shares under the company’s Non-Employee Directors Deferred Compensation Plan. On the transaction date, 199.2600 phantom shares were credited based on a reference price of $177.2500 per share of Danaher common stock.
Following this award, Stevens holds a total of 7,246.2860 phantom shares. Under the plan, deferred director fees and dividend accruals are converted into notional shares, which later convert into Danaher common stock on a one-for-one basis upon distribution. The reporting person is fully vested in all deferred amounts.
Danaher director Shane A. Sanders received a grant of 231.809 phantom shares linked to Danaher common stock at a reference price of $177.25 per share. This award comes through the company’s Non-Employee Directors Deferred Compensation Plan.
After this grant, Sanders holds 2,952.088 phantom shares, which are fully vested and convert into Danaher common stock on a one-for-one basis when distributed, providing additional equity-based compensation rather than an open-market stock purchase.
Danaher director Teri List received a grant of 17.248 phantom shares on the company’s non-employee director deferred compensation plan. The grant value was based on Danaher’s $177.25 closing stock price on the transaction date. After this award, List holds 7,660.399 phantom shares directly.
Under the plan, deferred cash director fees and dividend accruals are converted into notional shares using the quarter’s closing stock price. Upon distribution, these phantom shares convert into Danaher common stock on a one-for-one basis, and the reporting person is fully vested in all deferred amounts.
Danaher director Elias A. Zerhouni received a grant of phantom shares as part of deferred board compensation. On the reported date, 259.718 phantom shares tied to Danaher common stock were credited to his account at a reference price of $177.25 per share under the Non-Employee Directors Deferred Compensation Plan.
These phantom shares are fully vested, accrue dividends within the plan, and will convert into Danaher common stock on a one-for-one basis upon distribution. Following this grant, Zerhouni holds a total of 18,472.282 phantom shares directly under the plan.